Stefanie R Bailey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2957749/publications.pdf

Version: 2024-02-01

28 papers 2,002 citations

471509 17 h-index 752698 20 g-index

28 all docs

28 docs citations

times ranked

28

3418 citing authors

#	Article	IF	CITATIONS
1	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology, 2019, 37, 1049-1058.	17.5	347
2	When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cellular and Molecular Immunology, 2018, 15, 458-469.	10.5	331
3	Th17 Cells in Cancer: The Ultimate Identity Crisis. Frontiers in Immunology, 2014, 5, 276.	4.8	257
4	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRVIII CAR T cells in a preclinical model of human glioblastoma., 2019, 7, 304.		181
5	CAR T cell killing requires the IFNÎ ³ R pathway in solid but not liquid tumours. Nature, 2022, 604, 563-570.	27.8	150
6	Gene editing for immune cell therapies. Nature Biotechnology, 2019, 37, 1425-1434.	17.5	147
7	Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nature Communications, 2017, 8, 1961.	12.8	67
8	PI3KÎ' Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells. Frontiers in Immunology, 2017, 8, 1221.	4.8	56
9	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clinical Cancer Research, 2019, 25, 7046-7057.	7.0	56
10	Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight, 2017, 2, e90772.	5 . O	54
11	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell, 2022, 40, 494-508.e5.	16.8	54
12	Reducing CD73 Expression by IL1 \hat{I}^2 -Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors. Cancer Research, 2014, 74, 6048-6059.	0.9	49
13	Blockade or Deletion of IFNÎ ³ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. Blood Cancer Discovery, 2022, 3, 136-153.	5.0	46
14	Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunology, Immunotherapy, 2016, 65, 247-259.	4.2	35
15	$\hat{l}^2\text{-catenin}$ and PI3K \hat{l}' inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. JCI Insight, 2017, 2, .	5.0	35
16	Identification of human CD4 ⁺ T cell populations with distinct antitumor activity. Science Advances, 2020, 6, .	10.3	27
17	Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clinical Cancer Research, 2015, 21, 2546-2557.	7.0	25
18	Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning., 2016, 4, 6.		23

#	Article	IF	Citations
19	The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies. Journal of Immunology Research and Therapy, 2017, 2, 68-79.	1.0	20
20	Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation, 2017, 101, e75-e85.	1.0	15
21	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. , 2020, 8, e000990.		13
22	Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. Oncology Reviews, 2019, 13, 430.	1.8	9
23	Blocking IFN \hat{I}^3 in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity without Compromising Therapeutic Efficacy in CD19 +malignancies. Blood, 2021, 138, 1723-1723.	1.4	2
24	513â€CD26 enzymatic activity modulates efficient migration of adoptively transferred T cells to solid tumors. , 2020, 8, A549-A549.		1
25	767 Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies. , 2020, 8, A815-A815.		1
26	Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia. Blood, 2021, 138, 405-405.	1.4	1
27	221â€CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors. , 2021, 9, A234-A234.		0
28	Abstract 569: Mesothelin CAR T cells secreting FAP specific T cell engaging molecule (TEAM) target pancreatic cancer and its tumor microenvironment (TME). Cancer Research, 2022, 82, 569-569.	0.9	0